Drug Trial Radar · NCT06132126
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 17, 2023
Primary completion
Jun 28, 2024
Study completion Jun 28, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
Conditions
- Healthy
- Type 2 Diabetes Mellitus
Interventions
LY3938577Drug
Administered SC.
PlaceboDrug
Administered SC.
Insulin degludecDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationTime frame: Baseline up to 16 days
- Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administrationTime frame: Baseline up to 44 days
- Part A: Incidence of HypoglycemiaTime frame: Baseline up to 16 days
- Part B: Incidence of HypoglycemiaTime frame: Baseline up to 44 days
- Part A: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to 16 days
- Part B: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to 44 days
- Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to 16 days
- Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to 44 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CenExel ACT
Anaheim, California
Qps-Mra, Llc
Miami, Florida
Labcorp CRU
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.